184 related articles for article (PubMed ID: 1826594)
1. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon.
Gilbert DN; Wood CA; Kimbrough RC
Antimicrob Agents Chemother; 1991 Jan; 35(1):79-87. PubMed ID: 1826594
[TBL] [Abstract][Full Text] [Related]
2. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.
Van der Auwera P; Aoun M; Meunier F
Antimicrob Agents Chemother; 1991 Mar; 35(3):451-7. PubMed ID: 1828134
[TBL] [Abstract][Full Text] [Related]
3. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Reddy VN; Bailey EM; Rybak MJ
Antimicrob Agents Chemother; 1990 Nov; 34(11):2081-5. PubMed ID: 1963526
[TBL] [Abstract][Full Text] [Related]
4. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results.
Van Laethem Y; Hermans P; De Wit S; Goosens H; Clumeck N
J Antimicrob Chemother; 1988 Jan; 21 Suppl A():81-7. PubMed ID: 2965135
[TBL] [Abstract][Full Text] [Related]
5. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.
Asseray N; Jacqueline C; Le Mabecque V; Batard E; Bugnon D; Potel G; Caillon J
Antimicrob Agents Chemother; 2005 Feb; 49(2):857-9. PubMed ID: 15673789
[TBL] [Abstract][Full Text] [Related]
6. Activity of teicoplanin in localized experimental infections in rats.
Arioli V; Berti M; Candiani G
J Hosp Infect; 1986 Mar; 7 Suppl A():91-9. PubMed ID: 2871103
[TBL] [Abstract][Full Text] [Related]
7. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin.
Voorn GP; Kuyvenhoven J; Goessens WH; Schmal-Bauer WC; Broeders PH; Thompson J; Michel MF
Antimicrob Agents Chemother; 1994 Mar; 38(3):487-93. PubMed ID: 8203842
[TBL] [Abstract][Full Text] [Related]
8. [Teicoplanin versus cloxacillin, cloxacillin-gentamycin and vancomycin in the treatment of experimental endocarditis caused by methicillin-sensitive Staphylococcus aureus].
Apellaniz G; Valdés M; Pérez R; Martín-Luengo F; García A; Soria F; Gómez J
Enferm Infecc Microbiol Clin; 1991 Apr; 9(4):208-10. PubMed ID: 1830757
[TBL] [Abstract][Full Text] [Related]
9. A closer look at vancomycin, teicoplanin, and antimicrobial resistance.
Zeckel ML
J Chemother; 1997 Oct; 9(5):311-31; discussion 332-5. PubMed ID: 9373787
[TBL] [Abstract][Full Text] [Related]
10. [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].
Pham Dang C; Gouin F; Touchais S; Richard C; Potel G
Pathol Biol (Paris); 2001 Sep; 49(7):587-96. PubMed ID: 11642024
[TBL] [Abstract][Full Text] [Related]
11. Teicoplanin monotherapy of serious infections caused by gram-positive bacteria: a re-evaluation of patients with endocarditis or Staphylococcus aureus bacteraemia from a European open trial.
Davey PG; Williams AH
J Antimicrob Chemother; 1991 Apr; 27 Suppl B():43-50. PubMed ID: 1829076
[TBL] [Abstract][Full Text] [Related]
12. Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections.
Galanakis N; Giamarellou H; Vlachogiannis N; Dendrinos C; Daikos GK
Eur J Clin Microbiol Infect Dis; 1988 Apr; 7(2):130-4. PubMed ID: 2968907
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections.
Bibler MR; Frame PT; Hagler DN; Bode RB; Staneck JL; Thamlikitkul V; Harris JE; Haregewoin A; Bullock WE
Antimicrob Agents Chemother; 1987 Feb; 31(2):207-12. PubMed ID: 2952062
[TBL] [Abstract][Full Text] [Related]
14. The use of a new glycopeptide antibiotic, teicoplanin, in the treatment of bacterial endocarditis.
Webster A; Wilson AP; Williams AH; Treasure T; Grüneberg RN
Postgrad Med J; 1987 Aug; 63(742):621-4. PubMed ID: 2962071
[TBL] [Abstract][Full Text] [Related]
15. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.
Calain P; Krause KH; Vaudaux P; Auckenthaler R; Lew D; Waldvogel F; Hirschel B
J Infect Dis; 1987 Feb; 155(2):187-91. PubMed ID: 2949024
[TBL] [Abstract][Full Text] [Related]
16. Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.
Pavie J; Lefort A; Ploy MC; Massias L; Chau F; Garry L; Denis F; Fantin B
Antimicrob Agents Chemother; 2003 Jun; 47(6):2018-21. PubMed ID: 12760890
[TBL] [Abstract][Full Text] [Related]
17. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus.
Chambers HF; Sande MA
Antimicrob Agents Chemother; 1984 Jul; 26(1):61-4. PubMed ID: 6236747
[TBL] [Abstract][Full Text] [Related]
18. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study.
Huang JH; Hsu RB
Scand J Infect Dis; 2008; 40(6-7):462-7. PubMed ID: 18584532
[TBL] [Abstract][Full Text] [Related]
19. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis.
Kaatz GW; Seo SM; Dorman NJ; Lerner SA
J Infect Dis; 1990 Jul; 162(1):103-8. PubMed ID: 2141343
[TBL] [Abstract][Full Text] [Related]
20. Successful single-dose teicoplanin prophylaxis against experimental streptococcal, enterococcal, and staphylococcal aortic valve endocarditis.
Perdikaris GS; Pefanis A; Giamarellou H; Nikolopoulos A; Margaris EP; Donta I; Tsitsika A; Karayiannakos P
Antimicrob Agents Chemother; 1997 Sep; 41(9):1916-21. PubMed ID: 9303384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
